List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Ultra-micro oxygen sensor development

    SBC: Biocurrents Research, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall aim of this STTR proposal is to take an innovative, successful; laboratory based technology and transfer it to the commercial sector. Specifically, we wish to establish the capabilities within the Company to manufacture reliable, robust and inexpensive ultra-micro oxygen sensors suitable for electrochemical applications related to cellular metabolis ...

    STTR Phase I 2003 Department of Health and Human Services
  2. Novel pharmacotherapies for treatment of ADHD

    SBC: Biostream Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Attention-deficit hyperactivity disorder (ADHD) is a common neuropsychiatric condition characterized by hyperactivity, inattention and impulsivity, typically in school-aged boys. Psychostimulants, including methylphenidate and amphetamines, are commonly used to alleviate symptoms of ADHD. However, these medications are typically associated with undesirable sid ...

    STTR Phase I 2003 Department of Health and Human Services
  3. Development of a peptide array synthesis system

    SBC: Boston Array Technologies, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of phase I and II of this proposal is to develop microarray-based methods for high throughput profiling of proteins. This will be done in two different ways, one based on arrays of 100s of thousands of distinct peptides on 1 cm2 chips that can be used to fingerprint proteins, the other based on thousands or tens of thousands of antibodies again ...

    STTR Phase I 2003 Department of Health and Human Services
  4. Method for Discovering Novel Transcriptional Regulators

    SBC: CROSSLINK GENETICS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Regulation of gene expression by transcription factors is one of the most fundamental biological processes. The pharmaceutical manipulation of this process would open doors toward new approaches to treatment of cancer and other major diseases. We aim to develop a novel, comprehensive technology for manipulation of gene expression based on synthetic analogu ...

    STTR Phase I 2003 Department of Health and Human Services
  5. Method for Discovering Novel Transcriptional Regulators

    SBC: CROSSLINK GENETICS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Regulation of gene expression by transcription factors is one of the most fundamental biological processes. The pharmaceutical manipulation of this process would open doors toward new approaches to treatment of cancer and other major diseases. We aim to develop a novel, comprehensive technology for manipulation of gene expression based on synthetic analogu ...

    STTR Phase II 2003 Department of Health and Human Services
  6. Prevention of graft rejection by catalytic antioxidants

    SBC: Eukarion, Inc.            Topic: N/A

    DESCRIPTION (provided by the applicant): Transplantation represents the only therapy for end-stage organ failure caused by a variety of incurable diseases. However, rejection by the host represents a major obstacle to long-term survival of transplants. While acute rejection is currently controlled by immunosuppressive drugs, continuous treatment with these non-selective agents impairs the entire ...

    STTR Phase I 2003 Department of Health and Human Services
  7. Inhibition of corneal graft rejection by antioxidants

    SBC: Eukarion, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Corneal transplantation is the most common form of tissue allotransplantation (47,000 cases per year). However, 15% of the grafts are rejected within a year in "high risk" patients. In "low risk" patients, immunosuppressive drug treatment is associated with induction of cataracts, glaucoma and infections. In fact, despite the high rate of success, more corneal ...

    STTR Phase I 2003 Department of Health and Human Services
  8. Oral Therapeutic for Beta-Thalassemia

    SBC: Gene Regulation Laboratories            Topic: N/A

    DESCRIPTION (provided by applicant): The beta thalassemias are genetic disorders caused by molecular mutations affecting the genes for adult hemoglobin and are among the most common genetic diseases worldwide, although they comprise an orphan condition in the U.S. The beta thalassemia syndromes are characterized by excess alpha globin chains, which are toxic to the developing red blood cell and ca ...

    STTR Phase I 2003 Department of Health and Human Services
  9. Gene Therapy for Arthritis Using Lentiviral Vectors

    SBC: GENETIX PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Recent research has identified several proteins with potent anti-arthritic properties. Recombinant proteins, though, have limited half-lives in vivo and require repeated injection or infusion, daily in some cases, to maintain efficacy. Through the use of gene transfer, it is possible to deliver cDNAs encoding such proteins to the synovial lining of joints an ...

    STTR Phase I 2003 Department of Health and Human Services
  10. Transgenic Goats Produced by Germ Cell Transplantation

    SBC: GTC BIOTHERAPEUTICS, INC.            Topic: N/A

    N/A

    STTR Phase I 2003 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government